Abdominal Fat Clinical Trial
Official title:
Analysis of CoolSculpting by Zeltiq for Non-Invasive Cooling of Subcutaneous Fat of the Abdomen Using the eZ App Large Applicator
The purpose of this study is to evaluate the safety and efficacy of single treatment vs. multiple treatments of CoolSculpting™ by Zeltiq™ Aesthetics for non-invasive cooling of subcutaneous fat using the eZ App 8 large applicator on the abdomen for fat layer reduction.
Status | Completed |
Enrollment | 20 |
Est. completion date | February 2012 |
Est. primary completion date | November 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Male or female between the ages of 18 and 65 years of age. - Clearly visible fat on an area of the lower abdomen appropriate for treatment with the non-invasive Zeltiq cooling device. - Not had weight change fluctuations exceeding 5 pounds in the preceding 6 months. - Read and sign a written informed consent form. Exclusion Criteria: - Had liposuction, or another surgical procedure(s) or mesotherapy (injections of minute natural extracts, drugs and other agents into the skin to eliminate fat deposits in cellulite) in area of intended treatment within the past 2 years. - Had treatment with a cooling device within the past 6 months. (This exclusion does not apply to those enrolled in Group 3). - Known history of injections into the abdomen (e.g., cortisone) within the past 6 months. - Known history of cryoglobulinemia (abnormal blood proteins that thicken in cold temperatures), cold urticaria (large, allergic hives that occur when the skin is exposed to cold), or paroxysmal cold hemoglobinuria (sudden development of red blood cell breakdown causing hemoglobin [protein compound in blood] in the urine). - Used diet pills within the past 6 months. - Taking amino- or theophylline for asthma. - You are unable or unwilling to comply with the study requirements. - Any dermatological conditions or scars within the location of the treatment site that may interfere with the treatment or evaluation. - Currently enrolled in a clinical study of any other unapproved investigational drug or device. - Pregnant or intending to become pregnant in the next 9 months. - Breastfeeding or have been breastfeeding in the past 9 months. - Any other condition that would, in the professional opinion of the study doctor, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject. |
Observational Model: Cohort, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
United States | Laser & Skin Surgery Center of New York | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Laser and Skin Surgery Center of New York | Zeltiq Aesthetics |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02143960 -
VelaShape III Device in Comparison to Cryolipolysis for Circumferential Reduction
|
N/A | |
Active, not recruiting |
NCT01976247 -
A Pilot Study Testing a Noninvasive Cryolipolysis Device Versus a High Intensity Focused Ultrasound Device for Fat Reduction
|
N/A | |
Completed |
NCT02154113 -
Ultrashape System in Combination With VelaShape II Device for Circumferential Reduction
|
N/A | |
Completed |
NCT01239147 -
Effects of Whole Grain on Weight Maintenance
|
Phase 3 | |
Recruiting |
NCT05973526 -
Comparison of the Effects of Electric Current With Needles and Surface Electrodes on the Abdominal Contour of Women
|
N/A | |
Terminated |
NCT05388617 -
Study To Assess Radiofrequency Diathermocontraction Device For Muscle Stimulation And The Treatment Of Abdominal Fat
|
N/A | |
Completed |
NCT02873104 -
Pivotal Study of the truSculpt Radiofrequency Device for Circumferential Reduction
|
N/A | |
Completed |
NCT03428243 -
Long-term Follow-up Study of the truSculpt Radiofrequency Device for Circumferential Reduction
|
||
Completed |
NCT03811093 -
Comparing the Efficacy of a Dual-Frequency LLLT Device With a Sham Device as a Therapy for Adipose Tissue Loss
|
N/A | |
Recruiting |
NCT05779644 -
Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus
|
N/A |